M
Michaela Bosakova
Researcher at Masaryk University
Publications - 31
Citations - 394
Michaela Bosakova is an academic researcher from Masaryk University. The author has contributed to research in topics: Cilium & Tyrosine kinase. The author has an hindex of 10, co-authored 29 publications receiving 275 citations. Previous affiliations of Michaela Bosakova include Academy of Sciences of the Czech Republic.
Papers
More filters
Journal ArticleDOI
An inactivating mutation in intestinal cell kinase, ICK, impairs hedgehog signalling and causes short rib-polydactyly syndrome.
S. Paige Taylor,Michaela Bosakova,Miroslav Varecha,Lukas Balek,Tomáš Bárta,Lukáš Trantírek,Iva Jelínková,Ivan Duran,Iva Vesela,Kimberly N. Forlenza,Jorge H. Martin,Aleš Hampl,Michael J. Bamshad,Michael J. Bamshad,Deborah A. Nickerson,Margie Jaworski,Jieun Song,Hyuk Wan Ko,Daniel H. Cohn,Deborah Krakow,Pavel Krejci +20 more
TL;DR: Exome sequencing in a cohort of patients and identified homozygosity for a missense mutation in Intestinal Cell Kinase, ICK, identifies ICK as an SRPS-associated gene and reveals that abnormalities in signalling pathways contribute to defective skeletogenesis.
Journal ArticleDOI
The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases.
Bohumil Fafilek,Lukas Balek,Michaela Bosakova,Miroslav Varecha,Alexandru Nita,Tomas Gregor,Iva Gudernova,Jitka Krenova,Somadri Ghosh,Martin Piskacek,Lucie Jonatova,Nicole H. Cernohorsky,Jennifer Zieba,Michal Kostas,Ellen Margrethe Haugsten,Jørgen Wesche,Christophe Erneux,Lukáš Trantírek,Deborah Krakow,Pavel Krejci,Pavel Krejci +20 more
TL;DR: Loss of SHIP2 converted FGF-mediated sustained ERK activation into a transient signal and rescued cell phenotypes triggered by pathologic FGFR-ERK signaling, demonstrating that the adaptor rather than the catalytic activity ofSHIP2 was required.
Journal ArticleDOI
Computer-assisted engineering of hyperstable fibroblast growth factor 2.
Pavel Dvorak,David Bednar,Pavel Vanacek,Lukas Balek,Lívia Eiselleová,Veronika Stepankova,Eva Sebestova,Michaela Bosakova,Zaneta Konecna,Stanislav Mazurenko,Antonin Kunka,Tereza Vanova,Karolina Zoufalova,Radka Chaloupková,Jan Brezovsky,Pavel Krejci,Zbynek Prokop,Petr Dvorak,Jiri Damborsky +18 more
TL;DR: A generalizable computer‐assisted protein engineering strategy is used to create a unique modified FGF2 with nine mutations displaying unprecedented stability and uncompromised biological function.
Journal ArticleDOI
Regulation of ciliary function by fibroblast growth factor signaling identifies FGFR3-related disorders achondroplasia and thanatophoric dysplasia as ciliopathies
Michaela Bosakova,Miroslav Varecha,Marek Hampl,Marek Hampl,Ivan Duran,Alexandru Nita,Marcela Buchtová,Marcela Buchtová,Hana Dosedelova,Radek Machat,Radek Machat,Yangli Xie,Zhenhong Ni,Jorge H. Martin,Lin Chen,Gert Jansen,Deborah Krakow,Pavel Krejci +17 more
TL;DR: In vivo evidence for significantly shortened primary cilia in ACH and TD cartilage growth plates is reported and a FGF-cilia pathway is uncovered that needs consideration when elucidating the mechanisms of physiological and pathological FGFR function, or in the development of FGFR therapeutics.
Journal ArticleDOI
Nanodiamonds as “artificial proteins”: Regulation of a cell signalling system using low nanomolar solutions of inorganic nanocrystals
Lukas Balek,Marcela Buchtová,Michaela Bosakova,Miroslav Varecha,Silvie Foldynová-Trantírková,Iva Gudernova,Iva Vesela,Jan Havlik,Jitka Neburkova,Stuart Turner,Mateusz Adam Krzyscik,Malgorzata Zakrzewska,Lars Klimaschewski,Peter Claus,Lukáš Trantírek,Petr Cigler,Pavel Krejci +16 more
TL;DR: Nanosized diamond crystals (nanodiamonds, NDs) without any synthetically installed (bio)organic interface enable the specific and efficient targeting of the family of extracellular signalling molecules known as fibroblast growth factors (FGFs).